Q4 2022
Released Jan 31, 2023, before the open
10-K filed Feb 23, 2023, 54 days after period end · 0000078003-23-000024
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$15.75B$15.75B derived−2.7% vs Q4 2021−30.4% vs Q3 2022
Net Income$4.99B$4.99B derived+47.2% vs Q4 2021−42.0% vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived$8,582,000,000+45.1%
Free Cash Flowderived$7,581,000,000+54.3%
Margins · derived
Net margin31.7%+10.7 pt vs Q4 2021
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | $15.75B | $16.19B | $11.43B | $1.84B |
| Net Income | $4.99B | $3.39B | $846.00M | -$584.00M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR